title: Cytomegalovirus Pneumonia after Anti-CC-chemokine Receptor 4 Monoclonal Antibody (Mogamulizumab) Therapy in an Angioimmunoblastic T-cell Lymphoma Patient.
abstract: Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive T-cell lymphoma. A 63-year-old man was diagnosed with AITL. He received 6 cycles of CHOP therapy, but showed progressive disease. Subsequently, he received ESHAP chemotherapy; however, it was not effective. He received mogamulizumab (an anti-CCR4 monoclonal antibody). After 4 cycles, his respiratory condition worsened and he was diagnosed with cytomegalovirus (CMV) pneumonia. Despite antiviral and antibiotic therapy, he died. We speculate that the combination of progressive lymphoma with mogamulizumab and chemotherapy likely caused CMV pneumonia. Because mogamulizumab therapy causes immunosuppression, if CMV pneumonia is suspected, then rapid treatment should be initiated.
authors.affiliation: Department of Hematology, Yokohama City University Medical Center, Japan.
authors.forename: Yoshimi
authors.initials: Y
authors.lastname: Ishii
authors.forename: Megumi
authors.initials: M
authors.lastname: Itabashi
authors.forename: Ayumi
authors.initials: A
authors.lastname: Numata
authors.forename: Wataru
authors.initials: W
authors.lastname: Yamamoto
authors.forename: Kenji
authors.initials: K
authors.lastname: Motohashi
authors.forename: Maki
authors.initials: M
authors.lastname: Hagihara
authors.forename: Kenji
authors.initials: K
authors.lastname: Matsumoto
authors.forename: Shin
authors.initials: S
authors.lastname: Fujisawa
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects* / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D018450:Disease Progression; D004317:Doxorubicin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D005047:Etoposide / Q000008:administration & dosage; D017809:Fatal Outcome; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage; D008875:Middle Aged; D011024:Pneumonia, Viral / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology / Q000821:virology; D011241:Prednisone / Q000008:administration & dosage; D054398:Receptors, CCR4 / Q000037:antagonists & inhibitors*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000900:Anti-Bacterial Agents; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; C515354:CCR4 protein, human; D054398:Receptors, CCR4; D003561:Cytarabine; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D011241:Prednisone; D008775:Methylprednisolone; C549035:mogamulizumab